|
UBR7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.27530208615667E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.468100085944E-10 |
| Normal-vs-Stage2 |
1.980850E-03 |
| Normal-vs-Stage3 |
9.64669455427725E-11 |
| Normal-vs-Stage4 |
6.75719999954083E-08 |
| Stage1-vs-Stage2 |
4.387800E-02 |
| Stage1-vs-Stage3 |
1.776770E-01 |
| Stage1-vs-Stage4 |
4.659000E-01 |
| Stage2-vs-Stage3 |
6.937600E-03 |
| Stage2-vs-Stage4 |
3.276300E-02 |
| Stage3-vs-Stage4 |
7.844400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.26467758277249E-13 |
| Normal-vs-AfricanAmerican |
5.002300E-03 |
| Normal-vs-Asian |
9.60060000000373E-05 |
| Caucasian-vs-AfricanAmerican |
9.798200E-02 |
| Caucasian-vs-Asian |
1.036360E-01 |
| AfricanAmerican-vs-Asian |
7.172000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6321999307678E-10 |
| Normal-vs-Female |
1.79180004167279E-10 |
| Male-vs-Female |
2.091000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.47329995267864E-09 |
| Normal-vs-Age(41-60Yrs) |
9.90399984246437E-10 |
| Normal-vs-Age(61-80Yrs) |
7.71380004316313E-09 |
| Normal-vs-Age(81-100Yrs) |
1.643050E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.118600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.495800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.942400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.942000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.794200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.093000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.340600E-01 |
| Classical-VS-Follicular |
8.545800E-01 |
| Classical-VS-Other |
3.049600E-01 |
| Classical-VS-Normal |
8.03159982964985E-10 |
| Tall-VS-Follicular |
2.469800E-01 |
| Tall-VS-Other |
8.005200E-01 |
| Tall-VS-Normal |
7.0928999995612E-07 |
| Follicular-VS-Other |
4.003800E-01 |
| Follicular-VS-Normal |
1.01180000000589E-06 |
| Other-VS-Normal |
3.355700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.12520004424965E-09 |
| Normal-vs-N1 |
6.89330037495495E-10 |
| N0-vs-N1 |
4.507800E-02 |
|
|
